Table 1 Baseline patient characteristics
Characteristics | Total (n = 33) |
|---|---|
Age, years; median (IQR) | 59 (55–69) |
Sex | |
Male | 29 (87.9%) |
Female | 4 (12.1%) |
Smoking history | |
Yes | 25 (75.8%) |
No | 8 (24.2%) |
Alcohol history | |
Yes | 24 (72.7%) |
No | 9 (27.3%) |
Bodyweight loss | |
<10% | 30 (90.9%) |
≥10% | 3 (9.1%) |
ECOG performance status | |
0 | 15 (45.5%) |
1 | 18 (54.5%) |
Tumor location | |
Upper | 6 (18.2%) |
Middle | 12 (36.4%) |
Lower | 15 (45.5%) |
Primary tumor length (cm) | |
≤5 | 7 (21.2%) |
>5 | 26 (78.8%) |
Clinical T stage | |
T3 | 26 (78.8%) |
T4 | 7 (21.2%) |
Clinical N stage | |
N2 | 14 (42.4%) |
N3 | 19 (57.6%) |
Clinical M stage | |
M0 | 6 (18.2%) |
M1 | 27 (81.8%) |
Clinical TNM stage | |
IV | 33 (100%) |
Site of metastases | |
Distant lymph nodes | 22 (66.7%) |
Lung | 6 (18.2%) |
Liver | 1 (3.0%) |
Bone | 3 (9.1%) |
Spleen | 1 (3.0%) |
Adrenal gland | 1 (3.0%) |
